Merck and Luminex Corporation enter agreement
13 March 2013 | By Merck
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for AD...
List view / Grid view
13 March 2013 | By Merck
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for AD...
12 March 2013 | By Biogen Idec
“This regulatory submission marks another significant step..."
12 March 2013 | By Department of Health
Chief Medical Officer says global action is needed otherwise in 20 years we could see any one of us dying following minor surgery...
12 March 2013 | By Merck
IMPROVE-IT is an 18,141 patient event-driven trial...
11 March 2013 | By Boehringer Ingelheim
International peer-to-peer sharing...
11 March 2013 | By Abbott
Abbott announced positive long-term results...
11 March 2013 | By BASF
BASF Pharma Callanish has received approval to sell concentrated omega-3 fatty acids as active pharmaceutical ingredients...
11 March 2013 | By Catalent Pharma Solutions
Catalent announced two joint ventures...
11 March 2013 | By Boehringer Ingelheim
New data presented...
10 March 2013 | By Pfizer
Results from the REMINDER trial...
10 March 2013 | By Gilead Sciences
Gilead Sciences announced data from the Phase 4 TERISA study...
10 March 2013 | By Abbott
Data from the EVEREST II study...
9 March 2013 | By Merck
Results from the HPS2-THRIVE study...
7 March 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the submission of a Marketing Authorisation Application for albiglutide...
7 March 2013 | By Biosector 2
NovoPen® 5 has just been approved for launch in China...